Article 5DMXX Gam-COVID-Vac phase 3 trial results: 91·6% efficacy and well tolerated

Gam-COVID-Vac phase 3 trial results: 91·6% efficacy and well tolerated

by
from Hacker News on (#5DMXX)
Comments
External Content
Source RSS or Atom Feed
Feed Location http://news.ycombinator.com/rss
Feed Title Hacker News
Feed Link https://news.ycombinator.com/
Reply 0 comments